Cardiovascular Disease in MASLD: New Advances in Therapeutic Targets
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiovascular Medicine".
Deadline for manuscript submissions: 15 March 2026 | Viewed by 17
Special Issue Editor
Interests: diabetes; diabetes complications; cardiovascular disease; MASLD; Brugada syndrome; arrhythmias
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), represents the most common chronic liver condition worldwide and is now a key feature of metabolic syndrome. Among individuals with MASLD, cardiovascular disease (CVD) is the leading cause of mortality, far exceeding liver-related complications. This striking relationship highlights the urgent need for targeted clinical strategies that address both hepatic and cardiovascular outcomes.
Patients with MASLD often present with a constellation of cardiometabolic risk factors, including insulin resistance, dyslipidemia, systemic inflammation, and hypertension, all of which contribute to accelerated atherosclerosis and increased cardiovascular events. Despite this well-established link, clinical management of CVD in MASLD remains suboptimal, partly due to limited therapeutic options and the absence of specific clinical guidelines tailored to this population. Emerging pharmacologic agents, such as GLP-1 receptor agonists and SGLT2 inhibitors, along with novel lipid-modifying and anti-inflammatory therapies, have shown promise in addressing this dual burden.
Given the clinical importance of this intersection, the Journal of Clinical Medicine is pleased to announce a Special Issue entitled “Cardiovascular Disease in MASLD: New Advances in Therapeutic Targets”. This Issue is dedicated to advancing the clinical understanding and management of cardiovascular risk in MASLD through high-quality original research, clinical trials, and comprehensive reviews. We welcome contributions that explore diagnostic approaches, cardiovascular risk stratification tools, the therapeutic efficacy of emerging agents, and clinical guidelines aimed at improving patient outcomes.
We cordially invite you and your colleagues to submit your clinical research, observational studies, interventional trials, and expert reviews that shed light on this evolving field and contribute to shaping future standards of care.
Dr. Alfredo Caturano
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- MASLD
- cardiovascular disease (CVD)
- metabolic dysfunction
- steatotic liver disease
- insulin resistance
- dyslipidemia
- atherosclerosis
- inflammation
- GLP-1 receptor agonists
- SGLT2 inhibitors
- lipid-lowering therapies
- cardiometabolic risk
- clinical trials
- therapeutic targets
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
